Infections in lung transplant recipients

The optimal prescription of immunosuppressive pharmacotherapy balances the benefit of allograft tolerance and the risk of invasion from unwanted organisms. Advances in antimicrobial prophylaxis and treatment strategies have resulted in a decrease in the incidence and severity of certain infections; however, infections along with allograft rejection continue to be leading causes of morbidity and mortality among lung allograft recipients. Ultimately, a careful monitoring protocol and a high index of suspicion for infection requiring investigation and treatment are necessary in the ongoing care of lung transplant recipients. The approach to infections should be guided by the knowledge of the various factors that increase susceptibility to microorganisms and any previous culture and sensitivity results.